Dr. Jordi Monés to analize the most innovative therapies in geographic atrophy and AMD at the “6th World Congress on COPHy”

Dr. Jordi Monés, the ophthalmologist specialising in macula, retina and vitreous at the Institut de la Màcula, is to participate from 26-29 March at the Sixth World Congress on Controversies in Ophthalmology (COPHy). The event is organised by the Portuguese Ophthalmology Society and will be held in the Italian town of Sorrento, close to Naples.

On Friday 27, Dr. Monés will take part in two of the debates in the Retina Section. The first will look at the possibility of minimising the worsening of geographic atrophy with lampalizumab and its efficiency. The speakers at this debate will be Dr. Monés and Dr. Jayakrishna Ambati.

The Institut – led by Dr. Monés – is the first accredited european research site and the first center to treat patients in the CHROMA Study. The phase III trial will evaluate the safety and efficacy of lampalizumab and its potential to slow the progression of the Geographic Atrophy (GA) and Age-Related Macular Degeneration (AMD).

The following session will feature different lectures on neovascular (wet) macular degeneration and its relationship with the most innovative therapies such as ranibizumab, bevacizumab and aflibercept. Together with Dr Monés, the speakers will be Dr. Stephan Michels and Dr. Usha Chakravarthy,

The sixth edition of the Congress will attract around 900 ophthalmologists from around the world. It will host debate, examination and analysis of the most important topics to arise in the world of ophthalmology in 2014.

You can find all the information about the Congress at the following link.